<DOC>
	<DOCNO>NCT00118105</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Bevacizumab may also stop growth tumor cell block blood flow tumor . Giving capecitabine oxaliplatin together bevacizumab surgery may effective treatment liver metastasis . PURPOSE : This phase II trial study well give capecitabine oxaliplatin together bevacizumab work treat patient undergo surgery liver metastasis due colorectal cancer .</brief_summary>
	<brief_title>S0408 : Capecitabine , Oxaliplatin , Bevacizumab Pts Undergoing Surgery Liver Mets From Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine proportion patient resectable hepatic metastasis secondary colorectal cancer undergo surgical resection achieve R0 resection treatment neoadjuvant capecitabine , oxaliplatin , bevacizumab . - Determine probability non-progression ( i.e. , stable disease response [ complete partial , confirm unconfirmed ] ) patient treat regimen . - Compare proportion patient treat regimen undergo surgical resection achieve R0 resection describe literature . - Determine overall survival disease-free survival patient treat regimen . - Determine response positron emission tomography patient treat regimen . - Correlate clinical outcome expression biomarkers ( e.g. , thymidylate synthase , dihydropyrimidine dehydrogenase , thymidine phosphorylase , excision repair cross complement 1 , hTERT ) telomere length patient treat regimen . OUTLINE : This multicenter study . - Neoadjuvant therapy : Patients receive bevacizumab* IV 30-90 minute oxaliplatin IV 2 hour day 1 oral capecitabine twice daily day 1-14 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . NOTE : *Bevacizumab administer course 1-3 neoadjuvant therapy . - Surgery : Approximately 3-4 week completion neoadjuvant therapy , patient evaluate . Patients unresectable disease remove study . Patients resectable disease undergo surgical resection liver metastasis within 4-6 week completion neoadjuvant therapy . - Adjuvant therapy : Beginning least 28 day surgical resection , patient least stable disease completion neoadjuvant therapy receive 4 course adjuvant bevacizumab** , oxaliplatin , capecitabine neoadjuvant therapy . NOTE : **Bevacizumab administer course 1-4 adjuvant therapy . After completion study treatment , patient follow every 4 month disease progression every 6 month 3 year study entry . PROJECTED ACCRUAL : Approximately 35-65 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hepatic metastasis secondary colorectal cancer percutaneous hepatic biopsy Resectable hepatic metastasis follow : Minor resection ( i.e. , less hemihepatectomy ) Major resection ( i.e. , hemihepatectomy extend hepatectomy ) Bilobar resection ( include atypical resection ) Synchronous primary tumor hepatic metastasis allow Radiologic evidence hepatic metastasis multiphasic contrastenhanced spiral CT scan Resectable primary colorectal cancer place allow Measurable disease No evidence extrahepatic metastasis chest xray CT scan chest PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Hemoglobin ≥ 9.0 g/dL WBC ≥ 3,000/mm^3 Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Hepatic Bilirubin ≤ 2 time upper limit normal ( ULN ) SGOT SGPT ≤ 2.5 time ULN Renal Creatinine clearance ≥ 60 mL/min Urine protein/creatinine ratio &lt; 1 OR Urine protein &lt; 1 g 24hour urine collection Cardiovascular No uncontrolled hypertension ( i.e. , blood pressure &gt; 150/90 mm Hg ) History hypertension allow provide well control stable regimen antihypertensive therapy No arterial thromboembolic event within past 12 month , include follow : Transient ischemic attack Cerebrovascular accident Unstable angina Myocardial infarction No peripheral vascular disease ≥ grade 2 Other Not pregnant nursing Fertile patient must use effective contraception No preexist peripheral neuropathy ≥ grade 2 No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 6 month since prior adjuvant chemotherapy primary tumor No prior systemic chemotherapy metastatic disease No prior hepatic artery infusion chemotherapy metastatic disease Endocrine therapy Not specify Radiotherapy No prior radiotherapy metastatic disease Surgery More 7 day since prior colonoscopy fine needle aspiration More 28 day since prior major invasive surgery open biopsy Other At least 4 week since prior concurrent sorivudine brivudine No prior radiofrequency ablation metastatic disease No prior cryotherapy metastatic disease No prior ablative technique metastatic disease No concurrent cimetidine Concurrent ranitidine drug different antiulcer class allow No concurrent oral anticoagulation treatment thrombosis Concurrent warfarin ( 1 mg ) maintain patency central venous catheter allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
</DOC>